Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The phase 1 portion of this study is an open-label, multicenter, dose-escalation study of
1-month depot TAK-448 in adult males with prostate cancer who are either on gonadotropin
releasing hormone (GnRH) therapy or who might be eligible for GnRH therapy in the future. The
phase 2 portion of this study is an open-label, multicenter, randomized study in men with
prostate cancer that will confirm the testosterone- and prostate specific antigen (PSA)-
lowering potential of up to 2 dose levels of 1-month depot TAK-448.